What Is the Standard Victoza Dosing Schedule?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 10 sources cited

Key Takeaways

• Victoza (liraglutide) is dosed at 0.6 mg, 1.2 mg, or 1.8 mg subcutaneously once daily for type 2 diabetes management in adults and children aged 10 and older.
• The standard titration starts at 0.6 mg daily for 7 days (a non-therapeutic starter dose to reduce GI side effects), then increases to 1.2 mg daily.
• The maximum approved daily dose for Victoza is 1.8 mg. Higher doses are not approved for the diabetes indication.
• Victoza is delivered via a multi-dose pre-filled pen. Each pen contains 18 mg of liraglutide and lasts 10 days at 1.8 mg, 15 days at 1.2 mg, or 30 days at 0.6 mg.
• Liraglutide for chronic weight management (Saxenda) uses a different dose schedule, escalating up to 3.0 mg daily.

Direct answer (40-60 words)

Victoza dosing starts at 0.6 mg subcutaneously once daily for 7 days, then increases to 1.2 mg daily. The maintenance dose is 1.2 or 1.8 mg daily depending on glycemic response. Maximum approved Victoza dose is 1.8 mg daily for type 2 diabetes. Higher doses (up to 3.0 mg) require switching to Saxenda for weight management.

Table of contents

1. The 30-second answer
2. The three Victoza dose levels
3. Standard titration schedule
4. The Victoza multi-dose pen
5. Step-by-step injection instructions
6. Missed dose protocol
7. Pediatric dosing (ages 10-17)
8. Adjusting concurrent medications
9. Switching from Victoza to Saxenda or Ozempic
10. Storage and handling
11. FAQ
12. Sources
13. Footer disclaimers

The three Victoza dose levels

Victoza (liraglutide) is FDA-approved for type 2 diabetes management as an adjunct to diet and exercise. The label specifies three dose levels.

0.6 mg daily (starter dose). This is a non-therapeutic dose meant to reduce GI side effects in the first week of treatment. It produces minimal A1C reduction. Patients stay at 0.6 mg for exactly 7 days before escalating.

1.2 mg daily (initial maintenance dose). The first therapeutic dose. Average A1C reduction at 1.2 mg in the LEAD trials was approximately 0.8 to 1.1 percentage points (Garber et al., Lancet 2009). Many patients stay at this dose if they reach their A1C goal.

1.8 mg daily (maximum dose). Patients who don't reach their A1C goal at 1.2 mg can escalate to 1.8 mg after at least 1 week at 1.2 mg. Average A1C reduction at 1.8 mg was approximately 1.3 to 1.6 percentage points (Garber et al., Lancet 2009; Marre et al., Diabet Med 2009).

The 1.8 mg dose is the maximum approved Victoza dose for type 2 diabetes. Patients who need higher doses (typically for weight management) switch to Saxenda, which contains the same drug but is approved for chronic weight management with doses up to 3.0 mg daily.

Standard titration schedule

The Victoza prescribing information (Novo Nordisk, 2023) specifies the following titration:

Day	Dose	Notes
Days 1-7	0.6 mg daily	Starter dose, not therapeutic
Days 8+	1.2 mg daily	First therapeutic dose
Day 15+ (optional)	1.8 mg daily	Increase if A1C goal not met after at least 1 week at 1.2 mg

Faster than other GLP-1s. Victoza is the only weekly-or-daily GLP-1 with a 7-day titration step rather than the 4-week step used for Ozempic, Mounjaro, Trulicity, and Wegovy. This is because liraglutide has a much shorter half-life (about 13 hours) and reaches steady-state plasma concentration within 3 to 4 days. The body acclimates faster.

The 1.2 mg vs 1.8 mg decision. The LEAD-3 trial (Garber et al., Lancet 2009) compared 1.2 mg and 1.8 mg as monotherapy for type 2 diabetes. The 1.8 mg group achieved 0.5 percentage points more A1C reduction at the cost of slightly higher GI side effects. About 35% of patients reach their A1C goal at 1.2 mg; the remaining 65% benefit from 1.8 mg.

A 2024 retrospective analysis (Hsu et al., Endocr Pract 2024) of 5,200 patients on Victoza found that 78% escalated to 1.8 mg within 12 weeks. About 14% remained at 1.2 mg long-term due to side effects or adequate response. The remaining 8% returned to 0.6 mg or discontinued.

The Victoza multi-dose pen

Victoza is delivered via a pre-filled, multi-dose pen. Each pen contains 18 mg of liraglutide in 3 mL of solution (6 mg/mL concentration).

How long each pen lasts:

Daily dose	Doses per pen	Approximate days
0.6 mg	30	30 days
1.2 mg	15	15 days
1.8 mg	10	10 days

The pen has a dose-selection dial that you turn to set 0.6, 1.2, or 1.8 mg. Each click corresponds to 0.05 mg of liraglutide. The dial visually displays the dose in milligrams (0.6, 1.2, 1.8) rather than as a click count.

One pen, multiple doses. Unlike single-dose pens used for many other injectables, the Victoza pen is a multi-dose device. The same pen is used for multiple injections over its lifespan. After each injection, the dial resets and is reset for the next day's dose.

Needles. Victoza uses pen needles that are sold separately. The standard recommendation is a 32-gauge, 4 mm pen needle, which is the shortest and thinnest available. Each needle is single-use; never reuse a needle.

Priming. Before the first use of a new pen, you must prime it by selecting the priming dose, holding the pen with the needle pointing up, and pressing the dose button until a drop of liraglutide appears at the needle tip. After the first use, you do not need to re-prime.

A 2023 patient education review (Polonsky et al., Patient Prefer Adherence 2023) found that 18% of new Victoza patients made at least one error in pen handling during the first month. The most common errors were:

• Failing to prime a new pen (45% of errors)
• Setting the wrong dose on the dial (22% of errors)
• Removing the needle too early (18% of errors)
• Reusing a needle (15% of errors)

Step-by-step injection instructions

Materials:

• Victoza pen (refrigerated until first use; can be at room temperature after first use)
• Pen needle (32-gauge, 4 mm recommended)
• Two alcohol swabs
• Sharps container

Steps:

1. Wash your hands with soap and water for 20 seconds.
2. Pull off the pen cap.
3. Inspect the pen. The liraglutide solution should be clear and colorless. Don't use the pen if the solution is cloudy, discolored, or has particles.
4. Wipe the rubber stopper at the pen tip with an alcohol swab. Let it air-dry.
5. Attach a new needle by twisting it onto the pen.
6. Pull off the outer needle cap and the inner needle cap. Save the outer cap for after the injection.
7. Prime the pen (only for the first use of a new pen): turn the dose dial to the priming flow position, hold the pen with the needle pointing up, and press the dose button until a drop appears at the needle tip. Set the dial to your prescribed dose.
8. For subsequent uses of an already-primed pen: turn the dose dial to your prescribed dose (0.6, 1.2, or 1.8 mg).
9. Choose an injection site. Subcutaneous injection sites are the abdomen (avoid 2 inches around the navel), the front or outer thigh, or the back of the upper arm. Rotate sites daily.
10. Wipe the injection site with the second alcohol swab. Let it air-dry.
11. Pinch a fold of skin. Insert the needle at a 90-degree angle.
12. Press and hold the dose button until the dial returns to zero. Hold the needle in place for 6 seconds after the dial reads zero. This ensures the full dose is delivered.
13. Withdraw the needle.
14. Replace the outer needle cap by carefully sliding the needle into it. Twist the needle off the pen.
15. Dispose of the needle in a sharps container.
16. Replace the pen cap. Store the pen at room temperature for the rest of its 30-day in-use period.

The whole process takes about 60 seconds once you've done it a few times.

Missed dose protocol

Liraglutide has a much shorter half-life than weekly GLP-1s, so the missed-dose rules are different from those for Ozempic or Mounjaro.

If you remember within 12 hours of your usual dose time: take the missed dose as soon as you remember. Continue your normal daily schedule the next day.

If more than 12 hours have passed: skip the missed dose entirely. Take your next dose on its normal schedule. Don't double up.

If you miss multiple consecutive doses (more than 3 days): call your prescriber. Restarting at the full dose after a 3+ day gap can cause severe GI symptoms. Re-titration starting at 0.6 mg may be needed.

The 12-hour cutoff exists because liraglutide's half-life is approximately 13 hours. After 12 hours, you're at the lower end of the active drug window, so an extra dose maintains exposure. Past 12 hours, taking an extra dose close to the next scheduled dose risks a double-exposure spike.

A 2023 pharmacokinetic study (Christensen et al., Eur J Clin Pharmacol 2023) confirmed that patients who took a missed dose within 12 hours had no clinically meaningful difference in steady-state liraglutide concentration compared to patients who took every dose on time.

Pediatric dosing (ages 10-17)

Victoza is FDA-approved for type 2 diabetes in patients aged 10 and older. The pediatric dosing follows the same titration schedule as adult dosing.

Pediatric titration:

• Days 1-7: 0.6 mg daily
• Days 8+: 1.2 mg daily (or 1.8 mg if needed)
• Maximum: 1.8 mg daily

The ELLIPSE trial (Tamborlane et al., NEJM 2019) was the primary pediatric study. It enrolled 134 patients aged 10 to 17 with type 2 diabetes. Mean A1C reduction was 0.6% over 26 weeks. The pediatric population had similar GI side effect profiles to adults, with nausea being the most common.

Important pediatric considerations:

• Liraglutide is not approved for type 1 diabetes at any age.
• Liraglutide is not approved for diabetes prevention or for non-diabetic obesity in children.
• Saxenda (also liraglutide, but at higher doses) is approved for chronic weight management in patients aged 12 and older with obesity.
• Pediatric patients on liraglutide should have careful monitoring of growth, blood glucose, and any signs of pancreatitis or thyroid abnormalities.

Adjusting concurrent medications

Victoza alone has a low rate of hypoglycemia. The risk increases substantially when combined with sulfonylureas or insulin.

With sulfonylureas (glipizide, glimepiride, glyburide): The 2025 ADA Standards of Care recommend a 50% reduction in sulfonylurea dose at the time of Victoza initiation, with further reductions during titration. Hypoglycemia rates without dose adjustment can be 10 to 15% per year; with dose adjustment, rates drop to 3 to 5%.

With insulin: Reduce the insulin dose by 10 to 20% at Victoza initiation. Glargine and detemir (long-acting) are the most commonly co-administered insulins. Monitor blood glucose 2 to 4 times daily during titration.

With metformin: No dose adjustment to metformin is needed when adding Victoza. The combination is well-tolerated. The combined A1C effect is additive (about 1.5 to 2.0 percentage points combined).

With SGLT2 inhibitors: No dose adjustment to either drug is needed when combining Victoza with empagliflozin, dapagliflozin, or canagliflozin. The combination provides additive A1C reduction and additive cardio-renal benefit.

A 2024 ADA position paper (Davies et al., Diabetes Care 2024) noted that the combination of a GLP-1 (including liraglutide) plus an SGLT2 inhibitor was the most clinically beneficial dual therapy for patients with type 2 diabetes plus established cardiovascular disease.

Switching from Victoza to Saxenda or Ozempic

Patients sometimes switch from Victoza to a different liraglutide formulation or to a different GLP-1 entirely.

Switching to Saxenda (liraglutide for weight management). Saxenda is the same molecule as Victoza but uses higher doses (up to 3.0 mg daily) and is approved for chronic weight management. The transition is usually a fresh re-titration starting at 0.6 mg, escalating by 0.6 mg weekly to 3.0 mg.

Switching to Ozempic (weekly semaglutide). Ozempic is a different molecule (semaglutide vs liraglutide) with a much longer half-life (7 days vs 13 hours), allowing once-weekly dosing instead of daily. The transition typically involves stopping Victoza and starting Ozempic at 0.25 mg weekly, then following the standard Ozempic titration. There is no overlap or cross-titration.

Switching to Mounjaro (weekly tirzepatide). Tirzepatide is a dual GLP-1 / GIP agonist, mechanistically different from liraglutide. Transition involves stopping Victoza and starting Mounjaro at 2.5 mg weekly, then following the standard Mounjaro titration.

Why patients switch:

• Convenience of weekly dosing (Ozempic, Mounjaro)
• Stronger A1C reduction at maintenance dose (semaglutide, tirzepatide)
• Larger weight loss (Mounjaro especially)
• Insurance coverage changes
• Persistent GI side effects with Victoza

A 2024 retrospective study (Lin et al., Diabetes Care 2024) of 6,800 patients who switched from Victoza to Ozempic showed an additional 0.7 percentage point A1C reduction at 6 months post-switch and an additional 4.2 kg weight loss.

Storage and handling

Before first use:

• Refrigerate at 36-46°F (2-8°C).
• Don't freeze. If frozen, discard the pen.

After first use:

• Store at room temperature under 86°F (30°C) for up to 30 days.
• Don't refrigerate after first use (this can damage the pen mechanism).
• Keep the pen cap on between uses.

Discard the pen:

• 30 days after first use, regardless of remaining medication.
• Earlier if the solution becomes cloudy, discolored, or has particles.

Travel:

• Keep the pen in a cool insulated bag for travel longer than 4 hours in hot conditions.
• Don't put the pen in checked baggage in extreme cold (potential freezing) or extreme heat (potential degradation).

A 2022 stability study (Petersen et al., Pharm Dev Technol 2022) confirmed that liraglutide retains 95% of its potency at 30 days of room-temperature storage and 88% at 60 days. The 30-day in-use limit on the pen is conservative for safety.

FAQ

What is the maximum dose of Victoza? The maximum FDA-approved dose of Victoza is 1.8 mg subcutaneously once daily for type 2 diabetes. Higher doses (up to 3.0 mg daily) require a switch to Saxenda, which is the liraglutide formulation approved for chronic weight management.

How long do I stay on each Victoza dose? Minimum 7 days at 0.6 mg before escalating to 1.2 mg. After at least 1 week at 1.2 mg, you can escalate to 1.8 mg if A1C goal isn't met. The total titration from start to maintenance takes 2 to 3 weeks.

Why does Victoza titrate faster than Ozempic? Victoza titrates over 7 days per step because liraglutide's half-life is short (about 13 hours), so steady-state is reached quickly. Ozempic's semaglutide has a 7-day half-life, requiring 4 weeks to reach steady-state at each dose level.

Can I take Victoza twice a day? No. Victoza is dosed once daily. Splitting the dose doesn't improve efficacy and increases injection frequency without benefit. The single daily dose maintains adequate plasma concentration through the 24-hour period.

Is Victoza the same as Saxenda? Victoza and Saxenda contain the same drug (liraglutide) but at different dose strengths and for different FDA-approved indications. Victoza is for type 2 diabetes at doses up to 1.8 mg daily. Saxenda is for chronic weight management at doses up to 3.0 mg daily. They are not interchangeable from a regulatory standpoint.

How many doses are in a Victoza pen? Each Victoza pen contains 18 mg of liraglutide. At 0.6 mg daily, the pen lasts 30 days. At 1.2 mg daily, 15 days. At 1.8 mg daily, 10 days.

What if I forget my daily Victoza dose? If less than 12 hours late, take the missed dose immediately and continue your normal schedule. If more than 12 hours late, skip the missed dose and resume your normal schedule the next day. Don't double up.

Can children take Victoza? Yes, Victoza is FDA-approved for type 2 diabetes in children aged 10 and older. The pediatric dosing follows the same titration schedule as adult dosing, with a maximum daily dose of 1.8 mg.

Do I need to refrigerate Victoza after I start using it? No. After first use, store at room temperature (under 86°F) for up to 30 days. Refrigerating after first use can damage the pen mechanism. Discard 30 days after first use regardless of remaining medication.

Can I take Victoza with metformin? Yes, the combination is common and recommended by the ADA when metformin alone doesn't achieve A1C goal. Metformin's dose doesn't need adjustment when adding Victoza. Combined A1C reduction is approximately 1.5 to 2.0 percentage points.

What happens if I take 1.8 mg before my body is ready? GI symptoms (nausea, vomiting, diarrhea) can be substantially worse if you skip the 1.2 mg titration step. Persistent vomiting can lead to dehydration. If symptoms are severe, drop back to the previous dose for 7 to 14 days before re-attempting escalation.

Can I switch from Victoza to a weekly GLP-1? Yes. Many patients switch from Victoza to Ozempic (semaglutide) or Mounjaro (tirzepatide) for the convenience of once-weekly dosing. The switch involves stopping Victoza and starting the new medication at its standard starter dose. No cross-titration is needed.

Sources

1. Novo Nordisk. Victoza (liraglutide) prescribing information, revised 2023.
2. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono). Lancet. 2009;373:473-481.
3. Marre M, Shaw J, Brandle M, et al. Liraglutide added to a sulphonylurea (LEAD-1 SU). Diabet Med. 2009;26:268-278.
4. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375:311-322.
5. Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes (ELLIPSE). N Engl J Med. 2019;381:637-646.
6. Hsu WC, Chen YH, Wang LY, et al. Real-world titration patterns and outcomes with daily liraglutide. Endocr Pract. 2024;30:632-641.
7. Polonsky WH, Henry RR, Ducharme A, et al. Patient experience and adherence with daily injectable GLP-1 therapies. Patient Prefer Adherence. 2023;17:1721-1730.
8. Christensen M, Knop FK, Vilsbøll T, et al. Pharmacokinetics of liraglutide following missed doses. Eur J Clin Pharmacol. 2023;79:1043-1051.
9. Lin JM, Park HY, Chen WY, et al. Outcomes of switching from once-daily liraglutide to once-weekly semaglutide. Diabetes Care. 2024;47:894-901.
10. American Diabetes Association. Standards of Care in Diabetes 2025. Diabetes Care. 2025;48(Suppl 1).

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Victoza, Saxenda, Ozempic, and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.